Table 3.
Univariate and multivariate analysis of infection-related adverse events
| Any grade infection-related adverse events |
||||
|---|---|---|---|---|
| Univariate analysis |
Multivariate analysis |
|||
| Patients (%) | p-value | OR (95% CI) | p-value | |
| Age at diagnosis of metastatic CRC | 0.761 | - | - | |
| < 65 (n=124) | 33.1 | |||
| ≥ 65 (n=82) | 30.5 | |||
| Gender | 0.749 | - | - | |
| Male (n=141) | 31.2 | |||
| Female (n=65) | 33.8 | |||
| ECOG performance status | 0.847 | - | - | |
| 0, 1 (n=169) | 32.5 | |||
| ≥ 2 (n=37) | 29.7 | |||
| BMI (kg/m2) | - | - | ||
| < 25 (n=148) | 31.8 | 0.890 | ||
| ≥ 25 (n=58) | 32.8 | |||
| Comorbidity conditions by CCI scale | 0.025 | 2.54 (0.96-6.77) | 0.061 | |
| 0, 1 (n=186) | 29.6 | |||
| ≥ 2 (n=20) | 55.0 | |||
| Diabetes mellitus | 0.007 | - | - | |
| Yes (n=45) | 48.9 | |||
| No (n=161) | 27.3 | |||
| Hypertension | 0.873 | - | - | |
| Yes (n=65) | 30.8 | |||
| No (n=141) | 32.6 | |||
| Location of primary tumor | 0.456 | - | - | |
| Colon (n=110) | 34.5 | |||
| Rectum (n=96) | 29.2 | |||
| Stage | 0.152 | - | - | |
| M1a (n=64) | 25.0 | |||
| M1b (n=142) | 35.2 | |||
| No. of palliative chemotherapies | 0.636 | - | - | |
| 1 (n=121) | 31.4 | |||
| 2 (n=58) | 36.2 | |||
| ≥ 3 (n=27) | 25.9 | |||
| Use of dexamethasone | ||||
| Dose | - | 0.035 | - | - |
| Duration | - | 0.003 | 1.02 (1.00-1.03) | 0.008 |
| Use of megestrol acetate | ||||
| Dose | - | 0.038 | - | - |
| Duration | - | 0.016 | - | - |
| Mean glucose level (mg/dL) | 0.002 | 0.23 (0.09-0.58) | 0.002 | |
| Group 1 (n=52) | 11.5 | |||
| Group 2 (n=51) | 33.3 | |||
| Group 3 (n=51) | 41.2 | |||
| Group 4 (n=52) | 42.3 | |||
OR, odds ratio; CI, confidence interval; CRC, colorectal cancer; ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; CCI, Charlson Comorbidity Index; M1a, metastasis confined to one organ or site (e. g., liver, lung, ovary, or non-regional node); M1b, metastases in more than one organ/site or the peritoneum.